Abstract

Recent advances in cancer immunotherapy harness the immune system to precisely target cancer. These include the use of immunosuppressive agents, NK cell recovery, changes in tumor microenvironment metabolic, and aging to achieve a positive tumor response. The study explores the body development of the immune system in the late 19th century, highlighting milestones such as the discovery and FDA approval of IL2. Different categories of immunology are explored, from monoclonal antibodies to CART cell therapies, with emphasis on potential and challenges. It emphasizes the role of the immune system in cancer prevention and includes drugs that block the immune system, such as PD-1/PD-L1 and CTLA4 blockers, their approaches, clinical success, and combination therapies are discussed. The promising field of CAR-T cell therapy is broad, including technology, product development, challenges, future prospects and availability. In addition, oncolytic viruses such as T-VEC and HSV-1-based therapy show promise in cancer treatment. Ongoing research has been published on the treatment of oncolytic viruses for a variety of cancers, including triple negative breast cancer. Although challenges such as resistance to therapy remain, future developments include neoantigen vaccines, personalized medicine and nanomedicines to enhance drug delivery and reduce side effects. Immunotherapy dramatically extends patients’ lives and improves their quality of life, offering hope for advanced cancer treatment.
Keywords: Immunotherapy, cancer care, quality of life, Natural Killer (NK) cells, cytokine-based
therapies, tumor antigen escape
INTRODUCTION
Immunotherapy, a cancer treatment method, harnesses the body’s immune system to fight against
malignant cells. It has become an essential tool in cancer therapy due to its ability to specifically target cancerous cells while preserving the integrity of normal cells. Here are some noteworthy functions of immunotherapy in cancer treatment.

Keyworde: Immunotherapy, cancer care, quality of life, Natural Killer (NK) cells, cytokine-based therapies, tumor antigen escape

Full Text PDF Enter a number greater than 18 Submit

Refrences:

1. Aydin Ahmet Murat, et al. Prognostic significance of pre-and post-treatment PD-L1 expression in
patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG
immunotherapy. World J Urol. 2020; 38(10): 2537–2545.
2. Hosseini Reza, et al. Cancer exosomes and natural killer cells dysfunction: biological roles, clinical
significance and implications for immunotherapy. Mol Cancer. 2022; 21(1): 15(18p).
3. Zhao Lin, et al. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment
for immunotherapy in gastric cancer. Cell Death Dis. 2022; 13(4): 378.
4. Paffenholz Stella V, et al. Senescence induction dictates response to chemo-and immunotherapy in
preclinical models of ovarian cancer. Proc Natl Acad Sci. 2022; 119(5): e2117754119.
5. Zhang Yuanyuan, Zemin Zhang. The history and advances in cancer immunotherapy:
understanding the characteristics of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 2020; 17(8): 807–821.
6. Allison JP. A brief history of immunotherapy. Target Oncol. 2014; 3(1).
7. National Institutes of Health (NIH). Cancer Immunotherapy. (2020). [Online] Available from:
https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/promise-precisionmedicine/cancer-immunotherapy#:~:text=Decades%20of%20NIH%20research%20has,immune
%20system%20to%20attack%20tumors.
8. Finegold I. A brief history of allergen immunotherapy. Allergy & Asthma Proceedings. July 2022;
43(4): 248–253.
9. Khan Meshaal, Maker Ajay V, Shikha Jain. The evolution of cancer immunotherapy. Vaccines.
2021; 9(6): 614.
10. ACS. (2014). History of Cancer Treatments: Immunotherapy. [Online]. American Cancer Society.
www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-immunotherapy.
html.
11. Darvishi Mohammad, et al. Recent progress in cancer immunotherapy: Overview of current status
and challenges. Pathol Res Pract. 2023; 241: 154241.
12. Fa’ak Faisal, Adi Diab. Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors.
Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy: A Handbook for
Diagnosis and Management. Cham: Springer; 2021; 31–47.
13. Caruso Dean. Current and future directions for cancer immunotherapy Overview 102. Cancer
Forum, 2002; 26(2), 102–104.
14. Beckhove Philipp. Cancer immunotherapy: overview in brief. In: The Tumor Immunoenvironment.
Dordrecht: Springer; 2013; 549–565.
15. Tan Wei Chang Colin, et al. Overview of multiplex immunohistochemistry/immunofluorescence
techniques in the era of cancer immunotherapy. Cancer Commun. 2020; 40(4): 135–153.
16. Timmer Florentine EF, et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers.
2021; 13(16): 4138.
17. Mezni Essia, Khalil Behi, Anthony Gonçalves. Immunotherapy and breast cancer: An overview.
Curr Opin Oncol. 2022; 34(5): 587–594.
18. Li Xinxin, et al. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer.
2022; 21(1): 76.
19. Creemers Jeroen HA, et al. A tipping point in cancer-immune dynamics leads to divergent
immunotherapy responses and hampers biomarker discovery. J Immunother Cancer. 2021; 9(5):
e002032.
20. Sethna Zachary, et al. 824 High quality neoantigens are immunoedited in long-term pancreatic
cancer survivors. J Immunother Cancer. 2021; 9(Suppl 2): A1–A1054.
21. Bullock Timothy NJ. Fundamentals of cancer immunology and their application to cancer vaccines.
Clin Transl Sci. 2021; 14(1): 120–131.
22. Vu Tamara MSH, et al. Theranostics: a fifth pillar of contemporary cancer care? ANZ J Surg. 2022;
92(11): 2782.
23. Deng Yixin, et al. Introduction and Application of Death Protein 1. 2022 International Conference
on Biotechnology, Life Science and Medical Engineering (BLSME 2022). 2022; 367–376.
24. Huang Haoran, et al. T cell proliferation-related genes: Predicting prognosis, identifying the cold
and hot tumors, and guiding treatment in clear cell renal cell carcinoma. Front Genet. 2022; 13:
948734.
25. Sharifi Maryam, Jamshidi Arta A, Nazanin Namazi Sarvestani. An adaptive robust control strategy
in a cancer tumor-immune system under uncertainties. IEEE/ACM Transactions on Computational
Biology and Bioinformatics (TCBB). 2018; 16(3): 865–873.
26. Ertan Kubra, et al. The importance of systemic inflammatory response index, systemic immuneinflammation index, and hemoglobin-albumin-lymphocytes-platelets (HALP) score in children
with cancer. Iranian J Pediatr. 2021; 31(6): e118121.
27. Huang H, Wu K, Chen L, Lin X. Study on the application of systemic inflammation response index
and platelet-lymphocyte ratio in ovarian malignant tumors. International Journal of General
Medicine. Dec 2021; 14: 10015–10022.
28. Dang Yangjie, et al. The effect of anesthesia on the immune system in colorectal cancer patients.
Can J Gastroenterol Hepatol. 2018; 2018: 7940603.
29. Kaur KK, Allahbadia G, Singh M. Importance of controlling obesity and associated immune
response changes in prevention and treatment of cancer–with plant therapies of help. Adv Obes
Weight Manag Control. 2019; 9(4): 114–116.
30. Ahlmann Martina, Georg Hempel. The effect of cyclophosphamide on the immune system:
implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016; 78: 661–671.
31. Nair Varun Sasidharan, et al. Epigenetic regulation of immune checkpoints and T cell exhaustion
markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics. 2020; 12(21):
1871–1882.
32. Wang Ping-Huai, et al. The dynamic change of immune checkpoints and CD14+ monocytes in
latent tuberculosis infection. Biomedicines. 2021; 9(10): 1479.
33. Funes Samanta C, et al. Immune checkpoints and the regulation of tolerogenicity in dendritic cells:
implications for autoimmunity and immunotherapy. Autoimmun Rev. 2019; 18(4): 359–368.
34. Hu Min, et al. The regulation of immune checkpoints by the hypoxic tumor microenvironment.
Peer J. 2021; 9: e11306.
35. Ruedas-Torres Inés, et al. Up-regulation of immune checkpoints in the thymus of PRRSV-1-
infected piglets in a virulence-dependent fashion. Front Immunol. 2021; 12: 671743.
36. Shang Bing-Bing, et al. Significant correlation between HSPA4 and prognosis and immune
regulation in hepatocellular carcinoma. Peer J. 2021; 9: e12315.
37. Sasikumar Pottayil G, Murali Ramachandra. Small molecule agents targeting PD-1 checkpoint
pathway for cancer immunotherapy: mechanisms of action and other considerations for their
advanced development. Front Immunol. 2022; 13: 752065.
38. Godwin James L, et al. Immune checkpoint blockade as a novel immunotherapeutic strategy for
renal cell carcinoma: a review of clinical trials. Discov Med. 2014; 18(101): 341–350.
39. Zhou Xiaohan, et al. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal
cell carcinoma: from theoretical background to clinical reality. Front Oncol. 2020; 10: 1321.
40. Tenorio-Pedraza Juan Miguel, et al. Meta-analysis of preclinical measures of efficacy in immune
checkpoint blockade therapies and comparison to clinical efficacy estimates. Transl Med Commun.
2023; 8(1): 17.
41. Tang Xuzhen, et al. HuPBL humanized models as a tool to evaluate the efficacy and immune
regulation of immune checkpoint inhibitors. Cancer Res. 2017; 77(13_Suppl): 3849–3849.
42. Guo Linlin, et al. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits
potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models
and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology.
2022; 11(1): 2127691.
43. Chyuan I-Tsu, Ching-Liang Chu, Ping-Ning Hsu. Targeting the tumor microenvironment for
improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint
inhibitors and combination therapies. Cancers. 2021; 13(6): 1188.
44. Puri Sonam, Michael Shafique. Combination checkpoint inhibitors for treatment of non-small-cell
lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020;
9: 2019-9-2.
45. Cheu Jacinth Wing‐Sum, Carmen Chak‐Lui Wong. Mechanistic rationales guiding combination
hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology. 2021;
74(4): 2264–2276.
46. Maung Tun Zan, et al. Immune checkpoint inhibitors in lung cancer: role of biomarkers and
combination therapies. Cureus. 2020; 12(5): e8095.
47. Palmer Adam C, et al. Predictable clinical benefits without evidence of synergy in trials of
combination therapies with immune-checkpoint inhibitors. Clin Cancer Res. 2022; 28(2): 368–377.
48. Gong Jun, et al. Combination systemic therapies with immune checkpoint inhibitors in pancreatic
cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018; 7(1):
32(16p).
49. Pagel John M, Howard Jack West. Chimeric antigen receptor (CAR) T-cell therapy. JAMA Oncol.
2017; 3(11): 1595–1595.
50. Zhang C, Kasi A. Chimeric Antigen Receptor (CAR) T-Cell Therapy. Treasure Island, FL:
StatPearls; 2019.
51. Hofmann Susanne, et al. Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia
(AML). J Clin Med. 2019; 8(2): 200.
52. Sakoda Yukimi, Koji Tamada. Chimeric antigen receptor (CAR)-T cell therapy. Nihon rinsho
(Japanese Journal of Clinical Medicine). 2017; 75(2): 281–287.
53. Schubert M-L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Ann Oncol. 2021; 32(1): 34–48.
54. Fraietta Joseph A, et al. Determinants of response and resistance to CD19 chimeric antigen receptor
(CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018; 24(5): 563–571.
55. Dimitri Alexander, Friederike Herbst, Fraietta Joseph A. Engineering the next-generation of CAR
T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022; 21(1): 78.
56. Wagner Dimitrios L, et al. Sustainable clinical development of CAR-T cells–switching from viral
transduction towards CRISPR-Cas gene editing. Front Immunol. 2022; 13: 865424.
57. Agarwalla Pritha, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and
release of CAR-T cells. Nat Biotechnol. 2022; 40(8): 1250–1258.
58. Larson Rebecca C, Maus Marcela V. Recent advances and discoveries in the mechanisms and
functions of CAR T cells. Nat Rev Cancer. 2021; 21(3): 145–161.
59. Huckaby Justin T, et al. Bispecific binder redirected lentiviral vector enables in vivo engineering
of CAR-T cells. J Immunother Cancer. 2021; 9(9): e002737.
60. El-Daly Sherien M, Jihan Hussein. Genetically engineered CAR T-immune cells for cancer therapy:
recent clinical developments, challenges, and future directions. J Appl Biomed. 2019; 17(1): 11.
61. Poorebrahim Mansour, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest
advances and future prospects. Crit Rev Clin Lab Sci. 2019; 56(6): 393–419.
62. Srour Samer A, Serkan Akin. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The
Past and the Future. Journal of Immunotherapy and Precision Oncology (JIPO). 2023; 6(1): 19–30.
63. Gor Dhairya, et al. The Diagnostic and Treatment Challenges of Concomitant Mantle Cell
Lymphoma and IgM Myeloma. Eur J Case Rep Intern Med. 2022; 9(7): 003463.
64. Golubovskaya Vita, et al. Major highlights of the CAR-TCR Summit, Boston, 2016. Anti-Cancer
Agents Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2017; 17(10):
1344–1350.
65. Beck Caroline, et al. Tissue-specific targeting for cardiovascular gene transfer. Potential vectors
and future challenges. Curr Gene Ther. 2004; 4(4): 457–467.
66. Lauer Ulrich M, Julia Beil. Oncolytic viruses: challenges and considerations in an evolving clinical
landscape. Future Oncol. 2022; 18(24): 2713–2732.
67. Rahman Masmudur M, Grant McFadden. Oncolytic viruses: newest frontier for cancer
immunotherapy. Cancers. 2021; 13(21): 5452.
68. Tian Yaomei, Daoyuan Xie, Li Yang. Engineering strategies to enhance oncolytic viruses in cancer
immunotherapy. Signal Transduct Target Ther. 2022; 7(1): 117.
69. Heidbuechel Johannes PW, Engeland Christine E. Oncolytic viruses encoding bispecific T cell
engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021; 14(1): 1–24.
70. Malogolovkin Alexander, et al. Combinatorial approaches for cancer treatment using oncolytic
viruses: projecting the perspectives through clinical trials outcomes. Viruses. 2021; 13(7): 1271.
71. Suryawanshi Yogesh R, Schulze Autumn J. Oncolytic viruses for malignant glioma: On the verge
of success? Viruses. 2021; 13(7): 1294.
72. Goins William F, et al. Engineering HSV-1 vectors for gene therapy. Herpes Simplex Virus:
Methods and Protocols. 2014; 63–79.
73. Goins William F, et al. Engineering HSV-1 vectors for gene therapy. Herpes simplex virus:
Methods and protocols. 2020; 2060: 73–90.
74. Marinova Zhenya, et al. Oncolytic virotherapy-can a poliovirus cure cancer? Scr Sci Pharm. 2016;
3: 12.
75. Ye L, Chan T, Kryskiv O, Skoryk M. Scripta Scientifica Pharmaceutica. 2015; 1: 39–45. Scripta
Scientifica Pharmaceutica. [Online] Available at: https://journals.mu-varna.bg/index.php/ssp/index.
76. Li Mengyuan, et al. Preclinical and clinical trials of oncolytic vaccinia virus in cancer
immunotherapy: a comprehensive review. Cancer Biol Med. 2023; 20(9): 646–661.
77. Jin Shengye, et al. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res.
2021; 9(1): 71(6p).
78. Alayo Quazim, et al. IMMU-12. The Histone Deacetylase Inhibitor Valproic Acid Augments the
Susceptibility of Oncolytic Virus-Infected Glioblastoma Cells to PD-1 Blockade Therapy. NeuroOncology. 2017; 19(Suppl 6): vi115.
79. Goradel Nasser Hashemi, et al. Oncolytic virotherapy as promising immunotherapy against cancer:
mechanisms of resistance to oncolytic viruses. Future Oncol. 2021; 18(2): 245–259.
80. Miller Megan Jo, Kevin Chu Foy, Kaumaya Pravin TP. Cancer immunotherapy: present status,
future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med. 2013; 15(82):
166–176.
81. Peña Quim, et al. Metallodrugs in cancer nanomedicine. Chem Soc Rev. 2022; 51(7): 2544–2582.
82. Wurster Sebastian, Watowich Stephanie S, Kontoyiannis Dimitrios P. Checkpoint inhibitors as
immunotherapy for fungal infections: Promises, challenges, and unanswered questions. Front
Immunol. 2022; 13: 1018202.
83. Pan Ren-You, et al. Recent development and clinical application of cancer vaccine: targeting
neoantigens. J Immunol Res. 2018; 2018: 4325874.
84. Van Allen Eliezer. Abstract SY18-02: Immunogenomics and precision cancer medicine. Cancer
Res. 2016; 76(14_Supp): SY18–02.
85. Zhang Ning. Promoting the bench-to-bedside translation of nanomedicines. Med Rev. 2023; 3(1):
1–3.
86. Amin Saber, et al. Impact of immunotherapy on the survival of patients with cancer and brain
metastases. J Natl Compr Canc Netw. 2020; 18(7): 832–840.
87. Beaulieu Elizabeth, et al. Health-related quality of life in cancer immunotherapy: a systematic
perspective, using causal loop diagrams. Qual Life Res. 2022; 31(8): 2357–2366.
88. Kim Hongsik, et al. Long‐term outcomes in patients with advanced and/or metastatic non–small
cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable
response after discontinuation without disease progression: Multicenter, real‐world data (KCSG
LU20‐11). Cancer. 2022; 128(4): 778–787.
89. Fragkiadakis Georgios F, et al. Investigating the Quality of Life for Cancer Patients and Estimating
the Cost of Immunotherapy in Selected Cases. Cureus. 2022; 14(12): e32390.
90. Nadia Jaber. (2021 Apr 30). Study Details Long-Term Side Effects of Immune Checkpoint
Inhibitors. [Online]. National Cancer Institute. www.cancer.gov/news-events/cancer-currentsblog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects.